Report Detail
North America Vaccines Market to 2027 - Regional Analysis and Forecasts by Technology (Recombinant Vaccines, Conjugate Vaccines, Live Attenuated Vaccines, Inactivated and Subunit Vaccines, and Toxoid Vaccines); Disease Indication (DTP (Diphtheria Tetanus toxoids and Pertussis), Influenza, Hepatitis, Respiratory Syncytial Virus (RSV), and Other Diseases); Route of Administration (Oral, Injectable, and Other Routes of Administration); Patient Type (Pediatric Patients, and Adult Patients), and Coun
- RnM3446206 |
- 22 May, 2019 |
- Global |
- 142 Pages |
- The Insight Partners |
- Pharma & Healthcare
The North America vaccines market is expected to reach US$ 24,510.0 Mn in 2027 from US$ 14,566.0 Mn in 2018. The market is estimated to grow with a CAGR of 6.0% from 2019-2027.
The growth of the vaccines market is primarily attributed due to the compulsion or mandate vaccination and dropping vaccination rates. However, low awareness about the benefits of vaccines are likely to hinder the growth of the market during the forecast period. Additionally the growth of the North America vaccines market is contributed due to the factors such as investments made by the key players for various research and development activities as well as launch of new products in the US. In addition, extensive research in pharmaceutical and biotechnology companies further expected stimulate the growth of vaccines market in North America. The countries in the regions have face mandatory vaccinations legislation, the legislation was imposed to eradicate the deadly diseases such as measles, mumps and rubella vaccine from the country. For instance, US has the highest prevalence of the measles, it is among the most contagious diseases approximately one out of nine is expected to get measles if he or she is not immune. As per the recent data shared by the Centers for Disease Control and Prevention (CDC) it is stated that in 2018 US experienced approximately 17 cases. In US, cities such as New York State, New Jersey, and New York City has registered three major outbreak of the measles. Therefore, getting vaccinated or immunized is the best preventive measure thus, approximately in 50 states and the District of Columbia require students to be vaccinate before attending school. Owing to these factors the market is likely to grow significantly during the forecast period.
In 2018, the conjugate vaccines segment held a largest market share of 27.5% of the vaccines market, by technology. This segment is also expected to dominate the market in 2027 owing to advantages of the conjugate vaccines are their ability to elicit immunological memory and to reduce asymptomatic carriage of the bacteria, resulting in marked herd immunity. Moreover, the conjugate vaccines segment is anticipated to witness the significant growth rate of 6.7% during the forecast period, 2019 to 2027.
North America vaccines market by the disease indication was led by the others segments which has included diseases such as poliomyelitis (polio), measles, mumps, rubella, pneumococcal infections, and others. The segment has largest market share in 2018, which accounted 59.8% and is expected to dominate the market in 2027. Similarly, the vaccines market by the route of administration was led by the injectable segment. Whereas, the market of the vaccines in the North America by the patient type was led by the pediatric segment.
Some of the major primary and secondary sources for vaccines included in the report are Centers of Disease Control & Prevention, Food and Drug Administration, World Health Organization and Others.
TABLE OF CONTENTS
PART 1. INTRODUCTION
- 1.1 SCOPE OF THE STUDY
- 1.2 THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
PART 2. NORTH AMERICA VACCINES MARKET - KEY TAKEAWAYS
PART 3. NORTH AMERICA VACCINES MARKET - MARKET LANDSCAPE
- 3.1 OVERVIEW
- 3.2 MARKET SEGMENTATION
- 3.2.1 North America Vaccines Market - By Technology
- 3.2.2 North America Market - By Disease Indication
- 3.2.3 North America Vaccines Market - By Route of Administration
- 3.2.4 North America Vaccines Market - By Patient Type
- 3.2.5 North America Vaccines Market - By Country
- 3.3 PEST ANALYSIS
PART 4. NORTH AMERICA VACCINES MARKET- KEY MARKET DYNAMICS
- 4.1 KEY MARKET DRIVERS
- 4.1.1 Compulsion or Mandate Vaccination
- 4.1.2 Dropping Vaccination Rates
- 4.2 KEY MARKET RESTRAINTS
- 4.2.1 Low Awareness About the Benefits of Vaccines
- 4.3 KEY MARKET OPPORTUNITIES
- 4.3.1 Rising Numbers of Diseases
- 4.4 FUTURE TRENDS
- 4.4.1 Advances in Vaccine Technology
- 4.5 IMPACT ANALYSIS
PART 5. VACCINES MARKET - NORTH AMERICA ANALYSIS
- 5.1 NORTH AMERICA VACCINES MARKET REVENUE FORECASTS AND ANALYSIS
- 5.2 MARKET POSITIONING
- 5.3 PERFORMANCE OF KEY PLAYERS
PART 6. NORTH AMERICA VACCINES MARKET ANALYSIS - BY TECHNOLOGY
- 6.1 OVERVIEW
- 6.2 NORTH AMERICA VACCINES MARKET, BY TYPE, 2018 & 2027 (%)
- 6.3 NORTH AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY TECHNOLOGY (US$ MN)
- 6.4 NORH AMERICA RECOMBINANT VACCINES MARKET
- 6.4.1 Overview
- 6.4.2 North America Recombinant Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
- 6.5 NORTH AMERICA CONJUGATE VACCINES MARKET
- 6.5.1 Overview
- 6.5.2 North America Conjugate Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
- 6.6 NORTH AMERICA LIVE ATTENUATED VACCINES MARKET
- 6.6.1 Overview
- 6.6.2 North America Live Attenuated Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
- 6.7 NORTH AMERICA INACTIVATED VACCINES MARKET
- 6.7.1 Overview
- 6.7.2 North America Inactivated Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
- 6.8 NORTH AMERICA TOXOID VACCINES MARKET
- 6.8.1 Overview
- 6.8.2 North America Toxoid Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
PART 7. NORTH AMERICA VACCINES MARKET ANALYSIS - BY DISEASE INDICATION
- 7.1 OVERVIEW
- 7.2 NORTH AMERICA VACCINES MARKET, BY DISEASE INDICATION, 2018 & 2027 (%)
- 7.3 NORTH AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
- 7.4 NORTH AMERICA DTP (DIPHTHERIA, TETANUS, AND PERTUSSIS) MARKET
- 7.4.1 Overview
- 7.4.2 North America DTP (Diphtheria, Tetanus, And Pertussis) Market Revenue and Forecast to 2027 (US$ Mn)
- 7.5 NORTH AMERICA INFLUENZA MARKET
- 7.5.1 Overview
- 7.5.2 North America Influenza Market Revenue and Forecast to 2027 (US$ Mn)
- 7.6 NORTH AMERICA HEPATITIS MARKET
- 7.6.1 Overview
- 7.6.2 North America Hepatitis Market Revenue and Forecast to 2027 (US$ Mn)
- 7.7 NORTH AMERICA OTHER DISEASES MARKET
- 7.7.1 Overview
- 7.7.2 North America Other Diseases Market Revenue and Forecast to 2027 (US$ Mn)
PART 8. NORTH AMERICA VACCINES MARKET ANALYSIS - BY ROUTE OF ADMINISTRATION
- 8.1 OVERVIEW
- 8.2 NORTH AMERICA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2018 & 2027 (%)
- 8.3 NORTH AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
- 8.4 NORTH AMERICA ORAL MARKET
- 8.4.1 Overview
- 8.4.2 North America Oral Market Revenue and Forecast to 2027 (US$ Mn)
- 8.5 NORTH AMERICA INJECTABLE MARKET
- 8.5.1 Overview
- 8.5.2 North America Injectable Market Revenue and Forecast to 2027 (US$ Mn)
- 8.6 NORTH AMERICA OTHER ROUTES OF ADMINISTRATION MARKET
- 8.6.1 Overview
- 8.6.2 North America Other Routes of Administration Market Revenue and Forecast to 2027 (US$ Mn)
PART 9. NORTH AMERICA VACCINES MARKET ANALYSIS - BY PATIENT TYPE
- 9.1 OVERVIEW
- 9.2 NORTH AMERICA VACCINES MARKET, BY PATIENT TYPE, 2018 & 2027 (%)
- 9.3 NORTH AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
- 9.4 NORTH AMERICA PEDIATRIC MARKET
- 9.4.1 Overview
- 9.4.2 North America Pediatric Market Revenue and Forecast to 2027 (US$ Mn)
- 9.5 NORTH AMERICA ADULTS MARKET
- 9.5.1 Overview
- 9.5.2 North America Adults Market Revenue and Forecast to 2027 (US$ Mn)
PART 10. NORTH AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027
- 10.1 OVERVIEW
- 10.1.1 North America Vaccines Market Revenue And Forecasts to 2027 (US$ Mn)
- 10.1.2 North America Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
- 10.1.3 North America Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
- 10.1.4 North America Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
- 10.1.5 North America Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
- 10.1.6 North America Vaccines Market Revenue And Forecasts to 2027, By Country (%)
- 10.1.7 US Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
- 10.1.8 US Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
- 10.1.8.1 US Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
- 10.1.8.2 US Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
- 10.1.8.3 US Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
- 10.1.8.4 US Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
- 10.1.9 Canada Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
- 10.1.10 Canada Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
- 10.1.10.1 Canada Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
- 10.1.10.2 Canada Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
- 10.1.10.3 Canada Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
- 10.1.10.4 Canada Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
- 10.1.11 Mexico Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
- 10.1.12 Mexico Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
- 10.1.12.1 Mexico Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
- 10.1.12.2 Mexico Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
- 10.1.12.3 Mexico Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
- 10.1.12.4 Mexico Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
PART 11. VACCINES MARKET -INDUSTRY LANDSCAPE
- 11.1 OVERVIEW
- 11.2 COMPARATIVE COMPANY ANALYSIS
- 11.3 GROWTH STRATEGIES DONE BY THE COMPANIES IN THE MARKET, (%)
- 11.4 ORGANIC DEVELOPMENTS
- 11.4.1 Overview
- 11.5 INORGANIC DEVELOPMENTS
- 11.5.1 Overview
PART 12. VACCINES MARKET-KEY COMPANY PROFILES
- 12.1 PFIZER INC.
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Financial Overview
- 12.1.4 Product Portfolio
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
- 12.2 GLAXOSMITHKLINE PLC.
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Financial Overview
- 12.2.4 Product Portfolio
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
- 12.3 MERCK & CO., INC.
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Financial Overview
- 12.3.4 Product Portfolio
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
- 12.4 SANOFI
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Financial Information
- 12.4.4 Product Portfolio
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
- 12.5 JOHNSON & JOHNSON SERVICES, INC.
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Financial Overview
- 12.5.4 Product Portfolio
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
- 12.6 PANACEA BIOTEC LIMITED
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Financial Information
- 12.6.4 Product Portfolio
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
- 12.7 ASTELLAS PHARMA INC.
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Financial Overview
- 12.7.4 Product Portfolio
- 12.7.5 Swot Analysis
- 12.7.6 Key Developments
- 12.8 NOVAVAX, INC.
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Financial Information
- 12.8.4 Product Pipeline
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
- 12.9 VBI VACCINES INC.
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Financial Information
- 12.9.4 Product Portfolio
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
- 12.10 BAVARIAN NORDIC
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Financial Information
- 12.10.4 Product Pipeline
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
PART 13. APPENDIX
- 13.1 ABOUT THE INSIGHT PARTNERS
- 13.2 GLOSSARY OF TERMS
- 13.3 METHODOLOGY
- 13.3.1 Coverage
- 13.3.2 Secondary Research
- 13.3.3 Primary Research
LIST OF TABLES
TABLE 1. NORTH AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY TECHNOLOGY (US$ MN)
TABLE 2. NORTH AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
TABLE 3. NORTH AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 4. NORTH AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
TABLE 5. NORTH AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY TECHNOLOGY (US$ MN)
TABLE 6. NORTH AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
TABLE 7. NORTH AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 8. NORTH AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
TABLE 9. US VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY TECHNOLOGY (US$ MN)
TABLE 10. US VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
TABLE 11. US VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 12. US VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
TABLE 13. CANADA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY TECHNOLOGY (US$ MN)
TABLE 14. CANADA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
TABLE 15. CANADA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 16. CANADA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
TABLE 17. MEXICO VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY TECHNOLOGY (US$ MN)
TABLE 18. MEXICO VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
TABLE 19. MEXICO VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 20. MEXICO VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
TABLE 21. ORGANIC DEVELOPMENTS DONE BY COMPANIES
TABLE 22. INORGANIC DEVELOPMENTS DONE BY COMPANIES
TABLE 23. GLOSSARY OF TERMS, VACCINES MARKET
LIST OF FIGURES
FIGURE 1. US VACCINES MARKET, REVENUE (US$ MN), BY COUNTRY 2018 & 2027
FIGURE 2. NORTH AMERICA VACCINES MARKET BY TYPE, MARKET SHARE (%), 2018
FIGURE 3. NORTH AMERICA VACCINES MARKET BY DISEASE INDICATION, MARKET SHARE (%), 2018
FIGURE 4. NORTH AMERICA VACCINES MARKET BY ROUTE OF ADMINISTRATION, MARKET SHARE (%), 2018
FIGURE 5. NORTH AMERICA VACCINES MARKET BY PATIENT TYPE, MARKET SHARE (%), 2018
FIGURE 6. VACCINES MARKET SEGMENTATION
FIGURE 7. NORTH AMERICA PEST ANALYSIS
FIGURE 8. VACCINES MARKET IMPACT ANALYSIS OF DRIVERS & RESTRAINTS
FIGURE 9. NORTH AMERICA VACCINES MARKET - REVENUE FORECASTS AND ANALYSIS - 2018- 2027
FIGURE 10. NORTH AMERICA VACCINES MARKET, BY TECHNOLOGY, 2018 & 2027 (%)
FIGURE 11. NORTH AMERICA RECOMBINANT VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 12. NORTH AMERICA CONJUGATE VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 13. NORTH AMERICA LIVE ATTENUATED VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 14. NORTH AMERICA INACTIVATED VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 15. NORTH AMERICA TOXOID VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 16. NORTH AMERICA VACCINES MARKET BY DISEASE INDICATION, 2017 & 2025 (%)
FIGURE 17. NORTH AMERICA DTP (DIPHTHERIA, TETANUS, AND PERTUSSIS) MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 18. NORTH AMERICA INFLUENZA MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 19. NORTH AMERICA HEPATITIS MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 20. NORTH AMERICA OTHER DISEASES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 21. NORTH AMERICA VACCINES MARKET BY ROUTE OF ADMINISTRATION, 2018 & 2027 (%)
FIGURE 22. NORTH AMERICA ORAL MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 23. NORTH AMERICA INJECTABLE MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 24. NORTH AMERICA OTHER ROUTES OF ADMINISTRATION MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 25. NORTH AMERICA VACCINES MARKET BY PATIENT TYPE, 2018 & 2027 (%)
FIGURE 26. NORTH AMERICA PEDIATRIC MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 27. NORTH AMERICA ADULTS MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 28. NORTH AMERICA VACCINES MARKET REVENUE OVERVIEW, BY COUNTRY (2017) (US $ MN)
FIGURE 29. NORTH AMERICA MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 30. NORTH AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY COUNTRY (%)
FIGURE 31. US VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 32. CANADA VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 33. MEXICO VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 34. COMPARATIVE COMPANY ANALYSIS
FIGURE 35. GROWTH STRATEGIES DONE BY THE COMPANIES IN THE MARKET, (%)
Summary:
Get latest Market Research Reports on North America Vaccines . Industry analysis & Market Report on North America Vaccines is a syndicated market report, published as North America Vaccines Market to 2027 - Regional Analysis and Forecasts by Technology (Recombinant Vaccines, Conjugate Vaccines, Live Attenuated Vaccines, Inactivated and Subunit Vaccines, and Toxoid Vaccines); Disease Indication (DTP (Diphtheria Tetanus toxoids and Pertussis), Influenza, Hepatitis, Respiratory Syncytial Virus (RSV), and Other Diseases); Route of Administration (Oral, Injectable, and Other Routes of Administration); Patient Type (Pediatric Patients, and Adult Patients), and Coun. It is complete Research Study and Industry Analysis of North America Vaccines market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
